Optimising treatment duration with immunomodulators to reduce overtreatment (EME Programme): The Efficacy and Mechanism Evaluation (EME) Programme is accepting Stage 1 applications to their commissioned workstream. This is a cross-programme funding opportunity with the Health Technology Assessment (HTA) Programme who are also currently open to applications for this topic. All proposals submitted must fall within the scope of the EME Programme.

The Efficacy and Mechanism Evaluation (EME) Programme funds ambitious studies evaluating interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research in the mechanisms of diseases and treatments. EME is a partnership between the Medical Research Council (MRC) and the NIHR.The EME Programme looks to attract studies with novel methodological designs that deliver results more efficiently, reduce the study timeline, and maximise the knowledge gained. The translational research it supports covers a wide range of new and repurposed interventions, such as diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.